Cargando…
Proton therapy and the European Particle Therapy Network: The past, present and future()
Proton therapy is delivered to selected cancer patients presenting with rare tumours, for which a dose escalation paradigm and/or a reduced dose-bath to the organs at risk is pursued. It is a costly treatment with an additional cost factor of 2–3 when compared to photon radiotherapy. Notwithstanding...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395642/ https://www.ncbi.nlm.nih.gov/pubmed/32753239 http://dx.doi.org/10.1016/j.canrad.2020.05.002 |
_version_ | 1783565438949523456 |
---|---|
author | Weber, D.C. Langendijk, J.A. Grau, C. Thariat, J. |
author_facet | Weber, D.C. Langendijk, J.A. Grau, C. Thariat, J. |
author_sort | Weber, D.C. |
collection | PubMed |
description | Proton therapy is delivered to selected cancer patients presenting with rare tumours, for which a dose escalation paradigm and/or a reduced dose-bath to the organs at risk is pursued. It is a costly treatment with an additional cost factor of 2–3 when compared to photon radiotherapy. Notwithstanding the 180′000 patients treated with protons, scars robust clinical evidence is available to justify the administration of this treatment modality. The European Particle Therapy Network (EPTN) was created in 2015 to answer the critical European needs for cooperation among protons and carbon ions centres in the framework of clinical research networks. EPTN with other European groups will launch a number of prospective clinical trials that could be practice changing if positive. Alternative way to generate clinical data could be provided by alternative methodologies, such as the Dutch model-based approach, or could be provided by European infrastructure projects. |
format | Online Article Text |
id | pubmed-7395642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73956422020-08-03 Proton therapy and the European Particle Therapy Network: The past, present and future() Weber, D.C. Langendijk, J.A. Grau, C. Thariat, J. Cancer Radiother Short Communication Proton therapy is delivered to selected cancer patients presenting with rare tumours, for which a dose escalation paradigm and/or a reduced dose-bath to the organs at risk is pursued. It is a costly treatment with an additional cost factor of 2–3 when compared to photon radiotherapy. Notwithstanding the 180′000 patients treated with protons, scars robust clinical evidence is available to justify the administration of this treatment modality. The European Particle Therapy Network (EPTN) was created in 2015 to answer the critical European needs for cooperation among protons and carbon ions centres in the framework of clinical research networks. EPTN with other European groups will launch a number of prospective clinical trials that could be practice changing if positive. Alternative way to generate clinical data could be provided by alternative methodologies, such as the Dutch model-based approach, or could be provided by European infrastructure projects. Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. 2020-10 2020-08-01 /pmc/articles/PMC7395642/ /pubmed/32753239 http://dx.doi.org/10.1016/j.canrad.2020.05.002 Text en © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Weber, D.C. Langendijk, J.A. Grau, C. Thariat, J. Proton therapy and the European Particle Therapy Network: The past, present and future() |
title | Proton therapy and the European Particle Therapy Network: The past, present and future() |
title_full | Proton therapy and the European Particle Therapy Network: The past, present and future() |
title_fullStr | Proton therapy and the European Particle Therapy Network: The past, present and future() |
title_full_unstemmed | Proton therapy and the European Particle Therapy Network: The past, present and future() |
title_short | Proton therapy and the European Particle Therapy Network: The past, present and future() |
title_sort | proton therapy and the european particle therapy network: the past, present and future() |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395642/ https://www.ncbi.nlm.nih.gov/pubmed/32753239 http://dx.doi.org/10.1016/j.canrad.2020.05.002 |
work_keys_str_mv | AT weberdc protontherapyandtheeuropeanparticletherapynetworkthepastpresentandfuture AT langendijkja protontherapyandtheeuropeanparticletherapynetworkthepastpresentandfuture AT grauc protontherapyandtheeuropeanparticletherapynetworkthepastpresentandfuture AT thariatj protontherapyandtheeuropeanparticletherapynetworkthepastpresentandfuture |